about
Effect of low-magnitude whole-body vibration combined with alendronate in ovariectomized rats: a random controlled osteoporosis prevention studyPaget's disease of bone treated with a five day course of oral tiludronate.Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.The therapeutic use of bisphosphonates.Bisphosphonates in the treatment of metabolic bone diseases.Bisphosphonates: preclinical aspects and use in osteoporosis.Tiludronate inhibits interleukin-6 synthesis in osteoblasts: inhibition of phospholipase D activation in MC3T3-E1 cells.Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies.Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation.
P2860
Q28538486-1D1023F7-2E26-4752-A707-1D0C9331E23AQ33565205-EFED5A70-46A7-4289-8F0D-A3DE914FC739Q33898760-C22BF77D-3250-4DB8-BE4E-07FFF00CFD11Q33909532-463C2DAB-BB7F-4A40-B120-72FC4C6F75EEQ34216753-E4E9D6D0-7858-4ABF-ADBC-60834EEC93E1Q34272981-FE8AAB17-AD08-4977-A265-CF70DF806EA4Q36886733-986711BE-6F42-496A-9277-242BD1ECD2BFQ40769942-E2E8C23E-9616-4B51-8CD5-F04FEB3C9837Q41387009-16CC0365-242B-47E3-886B-9BF49BE9FC62Q42830360-7CD34D8F-76BF-4334-9B2D-D1765EC3AA06Q44429750-B4028C85-844A-4C44-A53C-0F3F1D1F18B2Q52871485-AEA4A0F4-97AE-4755-9A21-F686361547E4
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Prevention of postmenopausal bone loss by tiludronate.
@en
type
label
Prevention of postmenopausal bone loss by tiludronate.
@en
prefLabel
Prevention of postmenopausal bone loss by tiludronate.
@en
P2093
P1433
P1476
Prevention of postmenopausal bone loss by tiludronate.
@en
P2093
J Collette
J Y Reginster
M P Lecart
P Franchimont
P304
P356
10.1016/S0140-6736(89)92927-9
P407
P433
P577
1989-12-01T00:00:00Z